Achieve Life Sciences (ACHV) Cash from Investing Activities (2010 - 2026)
Achieve Life Sciences (ACHV) posted Cash from Investing Activities of $14.3 million for Q1 2026, up 1913.54% on a QoQ basis from $709000.0 in Q4 2025, and up 25.75% year-over-year from $11.4 million in Q1 2025.
Achieve Life Sciences (ACHV) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at $14.3 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 25.75% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 75.14% YoY) and the FY2025 annual result came in at $6.1 million, up 128.32% from the prior year.
- Cash from Investing Activities was $14.3 million for Q1 2026 at Achieve Life Sciences, up from $709000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $14.3 million in Q1 2026 and bottomed at -$12.7 million in Q3 2025.
- A 4-year average of $5.7 million and a median of $9.0 million in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 195383.33% — and 2025, when it plunged 195.35%.
- Achieve Life Sciences' Cash from Investing Activities stood at -$6000.0 in 2023, then soared by 195383.33% to $11.7 million in 2024, then tumbled by 93.95% to $709000.0 in 2025, then surged by 1913.54% to $14.3 million in 2026.
- Business Quant data shows ACHV's Cash from Investing Activities at $14.3 million in Q1 2026, $709000.0 in Q4 2025, and -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Achieve Life Sciences | 329.63 Mn | 329.63 Mn | - | 14.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.28 Mn |
| Mar 31, 2026 | 14.28 Mn |
| Dec 31, 2025 | 709,000.00 |
| Dec 31, 2025 | 709,000.00 |
| Sep 30, 2025 | -12.65 Mn |
| Sep 30, 2025 | -12.65 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Mar 31, 2025 | 11.35 Mn |
| Mar 31, 2025 | 11.35 Mn |
| Dec 31, 2024 | 11.72 Mn |
| Dec 31, 2024 | 11.72 Mn |
| Sep 30, 2024 | 13.27 Mn |
| Sep 30, 2024 | 13.27 Mn |
| Dec 31, 2023 | -6,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Jun 30, 2020 | -12,000.00 |
| Jun 30, 2020 | -12,000.00 |